Bluth Martin H, Norowitz Kevin B, Chice Seto, Shah Vipin N, Nowakowski Maja, Josephson Alan S, Durkin Helen G, Smith-Norowitz Tamar A
Department of Pathology, S.U.N.Y. Downstate Medical Center, Brooklyn, NY 11203, USA.
Clin Immunol. 2003 Aug;108(2):152-8. doi: 10.1016/s1521-6616(03)00098-6.
The immune profile of a parvovirus B19-infected patient (male, 8 years old) was studied on day 0 (initial presentation) and on days 14 and 210 post symptom presentation (psp). Before infection, the patient was skin test positive to various allergens, including ragweed and tree and grass pollens, and had a serum IgE level of 150 IU/mL. On day 0, the patient was diagnosed as parvovirus B19 infected, as judged by the presence of IgG anti-parvovirus Abs in serum (EIA) and presentation of "slap cheek" rash. The patient's serum IgE level increased from 150 IU/mL before infection to 256 IU/mL on day 0, was 233 IU/mL on day 14, and returned to preinfection levels on day 210. In contrast, there was little change in the levels of serum IgM, IgG, or IgA (nephelometry). IgE anti-parvovirus B19 protein (VP-N) was detected in serum (Western blot) on days 0, 14, and 210, despite the decrease in total IgE on day 210. Although there was no increase in total numbers of blood CD23+ B cells on day 0, by day 14 the numbers of these cells increased dramatically (93%), remaining high on day 210. In contrast, there were virtually no changes in total numbers of CD4+ and CD8+ T cells or CD16/56+ NK precursor cells on days 0-210. On day 0, when IgG and IgE anti-parvovirus were detected in serum, patient's peripheral blood mononuclear cells (PBMC) expressed mRNA for the Th2 cytokines IL-4 and IL-10, but not for the Th1 cytokines IFN-gamma or IL-2. However, by day 14 psp, PBMC expressed mRNA for the Th1 cytokines IFN-gamma and IL-2, as well as for IL-4 and IL-10. This is the first demonstration of the existence of IgE anti-parvovirus B19 Ab. The presence of IgE anti-parvovirus B19 Ab in serum on day 0 and its persistence in serum 7 months psp suggests that IgE anti-parvovirus may be useful in prognosis of parvovirus B19 infection. Our results reinforce the idea that IgE, in general, may play a major role in anti-viral immunity, perhaps in conjunction with CD23+ cells. The results further suggest that clearance of this infection is accompanied by a switch to Th1 cytokines.
对一名细小病毒B19感染患者(8岁男性)在第0天(初次就诊)以及症状出现后第14天和第210天的免疫情况进行了研究。感染前,该患者对多种过敏原(包括豚草、树木和草花粉)皮肤试验呈阳性,血清IgE水平为150 IU/mL。在第0天,根据血清中IgG抗细小病毒抗体(酶免疫测定法)的存在以及“ slapped cheek”皮疹的表现,该患者被诊断为细小病毒B19感染。患者的血清IgE水平从感染前的150 IU/mL在第0天升至256 IU/mL,在第14天为233 IU/mL,并在第210天恢复到感染前水平。相比之下,血清IgM、IgG或IgA水平(散射比浊法)几乎没有变化。尽管在第210天总IgE有所下降,但在第0天、第14天和第210天的血清中均检测到了IgE抗细小病毒B19蛋白(免疫印迹法)。尽管在第0天血液中CD23 + B细胞总数没有增加,但到第14天这些细胞的数量急剧增加(93%),在第210天仍保持高位。相比之下,在第0 - 210天,CD4 +和CD8 + T细胞总数或CD16/56 + NK前体细胞总数几乎没有变化。在第0天,当血清中检测到IgG和IgE抗细小病毒时,患者的外周血单个核细胞(PBMC)表达了Th2细胞因子IL-4和IL-10的mRNA,但未表达Th1细胞因子IFN-γ或IL-2的mRNA。然而,到症状出现后第14天,PBMC表达了Th1细胞因子IFN-γ和IL-2以及IL-4和IL-10的mRNA。这是首次证明存在IgE抗细小病毒B19抗体。在第0天血清中存在IgE抗细小病毒B19抗体并在症状出现后7个月在血清中持续存在,这表明IgE抗细小病毒可能对细小病毒B19感染的预后有用。我们的结果强化了这样一种观点,即一般而言,IgE可能在抗病毒免疫中起主要作用,可能与CD23 +细胞协同作用。结果进一步表明,这种感染的清除伴随着向Th1细胞因子的转变。